Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 6/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13937013 | 0.93 | NR1I2 (0.56) | NR1I2KCNH2SCN9ACYP3A4SCN5A | |
| SCHEMBL13937012 | 0.92 | NR1I2 (0.67) | NR1I2KCNH2SCN9ACYP3A4SCN5A | |
| SCHEMBL4828013 | 0.91 | NR1I2 (0.68) | NR1I2KCNH2SCN9ACYP3A4SCN5A | |
| SCHEMBL13937014 | 0.90 | NR1I2 (0.57) | NR1I2KCNH2SCN9ACYP3A4SCN5A | |
| SCHEMBL13868755 | 0.88 | NR1I2 (0.54) | NR1I2KCNH2SCN9ACYP3A4SCN5A | |
| SCHEMBL51250 | 0.88 | KCNH2 (0.56) | NR1I2KCNH2SCN9ACYP3A4SCN5A | |
| SCHEMBL50868 | 0.88 | KCNH2 (0.56) | NR1I2KCNH2SCN9ACYP3A4SCN5A | |
| SCHEMBL13841837 | 0.87 | NR1I2 (0.55) | NR1I2KCNH2SCN9ACYP3A4SCN5A | |
| SCHEMBL14149284 | 0.86 | KCNH2 (0.55) | NR1I2KCNH2SCN9ACYP3A4SCN5A | |
| SCHEMBL13791861 | 0.85 | NR1I2 (0.52) | NR1I2KCNH2SCN9ACYP3A4SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485633-B2 | RNA polymerase, HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase inhibitor; liver disease; (+/-)-8-Cyclohexyl-N-4-(morpholinosulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-(3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)cycloprop[d]indolo[2,1-a][2]benzazepine-5-carboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485633-B2 | RNA polymerase, HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase inhibitor; liver disease; (+/-)-8-Cyclohexyl-N-4-(morpholinosulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-(3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)cycloprop[d]indolo[2,1-a][2]benzazepine-5-carboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-03 | — | — | US | disclosed |
| WO-2008111978-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20070184024-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-09 | — | — | US | disclosed |
| US-20070184024-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070184024-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | ZC3HAV1, CYP3A5, SLC10A1 | NR1I2 201/4885KCNH2 934/4885SCN9A 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.